These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Zomedica Pharmaceuticals (ZOM – Research Report) today and set a price target ...
For columnist Alyssa Silva, advances in the development of SMA treatments have felt like glimmers of miracles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback